Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient population for this type of therapy is now pressing. While specific biomarker assays have been developed for these checkpoint inhibitors based on their respective epitopes, the available studies suggested the clinical utility of these biomarker assays is for response stratification and not patient selection. Further improvement in assay development is needed to utilize this type of assay in identification of ideal patient population for this therapy.

• Publication year

  2017

• Venue

  Biomarker Research

• Publication date

  2017-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s40364-017-0093-8PMID 28331612PMCID 5353958
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.

  2017cited by this paper
• Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition

  2017cited by this paper
• PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project

  2017cited by this paper
• PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD‐L1–Selected Chemotherapy‐Naive NSCLC Patients: Topic: Medical Oncology

  2016cited by this paper
• Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

  2016cited by this paper
• Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

  2016cited by this paper
• Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

  2016cited by this paper
• Kidney cancer: Papillary features predict survival in ncRCC

  2016cited by this paper
• Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.

  2016cited by this paper
• Results from a Train-the-Trainer Communication Program for Oncology Nurses.

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

  2016influential reference
• Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

  2016cited by this paper
• Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

  2016cited by this paper
• A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.

  2016influential reference
• Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

  2016cited by this paper
• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

  2016cited by this paper
• Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

  2016cited by this paper
• Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

  2016cited by this paper
• Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

  2016cited by this paper
• Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.

  2016cited by this paper
• Combined BRAF and MEK inhibition in BRAF-mutant NSCLC.

  2016cited by this paper
• Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

  2016influential reference
• Skin cancer: Avelumab effective against Merkel-cell carcinoma

  2016cited by this paper
• Anti-PD-L1 inhibitor durvalumab in bladder cancer.

  2016influential reference
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

  2016cited by this paper
• Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

  2015cited by this paper
• Comprehensive genomic characterization of head and neck squamous cell carcinomas

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Therapie des unbehandelten lokal fortgeschrittenen oder metastasierten Nierenzellkarzinoms

  2015cited by this paper
• Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

  2015cited by this paper
• Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

  2015cited by this paper
• Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer

  2015cited by this paper
• The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.

  2015cited by this paper
• Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

  2015cited by this paper
• Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

  2015influential reference
• Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.

  2015cited by this paper
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• 15LBA High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients

  2015cited by this paper
• CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

  2015cited by this paper
• Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Pidilizumab in the treatment of diffuse large B-cell lymphoma

  2014cited by this paper
• Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant non-small cell lung cancer in never-smokers.

  2014cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014cited by this paper
• Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

  2014cited by this paper
• PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.

  2014cited by this paper
• Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center.

  2014cited by this paper
• Molecular Pathways Molecular Pathways : The Immunogenic Effects of Platinum-Based Chemotherapeutics

  2014cited by this paper
• Quantitative Measurement of Cancer Tissue Biomarkers in the Lab and in the Clinic

  2014cited by this paper
• PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.

  2014cited by this paper
• LBA43ANTITUMOR ACTIVITY OF PEMBROLIZUMAB (PEMBRO; MK-3475) AND CORRELATION WITH PROGRAMMED DEATH LIGAND 1 (PD-L1) EXPRESSION IN A POOLED ANALYSIS OF PATIENTS (PTS) WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA (NSCLC)

  2014cited by this paper
• Harnessing the immune system for the treatment of non-small-cell lung cancer.

  2013cited by this paper
• Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study

  2012cited by this paper
• PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.

  2009cited by this paper
• Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma

  2008cited by this paper
• Immune suppression in the tumor microenvironment.

  2006cited by this paper
• Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

  2003cited by this paper

• Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer

  2026cites this paper
• Synergistic Anticancer Effects of Apatinib and PD-L1 Inhibition in Breast Cancer

  2026cites this paper
• Circulating Tumor DNA in Melanoma: Advances in Detection, Clinical Applications, and Integration with Emerging Technologies

  2026cites this paper
• High-sensitivity PD-L1 immune checkpoint imaging in microtumors for immunotherapy using near-infrared persistent luminescence nanoparticles.

  2025cites this paper
• A CT-based interpretable deep learning signature for predicting PD-L1 expression in bladder cancer: a two-center study

  2025cites this paper
• Gold nanoparticles in imaging: advances, applications, and future perspectives

  2025cites this paper
• Navigating the latest advancement & frontiers in cancer immunotherapy

  2025cites this paper
• CT-Based Radiomics for Predicting PD-L1 Expression in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.

  2025cites this paper
• A narrative review of the prediction of immunotherapy efficacy for treating NSCLC: An artificial intelligence perspective

  2025cites this paper
• The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients

  2025cites this paper
• p53/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma

  2025cites this paper
• Radiosynthesis and preclinical evaluation of [99mTc]Tc-HYNIC–durvalumab for immuno-SPECT imaging of PD-L1 expression in tumor models

  2025cites this paper
• The branched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCC

  2024cites this paper
• Omics-based molecular classifications empowering in precision oncology

  2024cites this paper
• WTAP‐induced N 6 ‐methyladenosine of PD‐L1 blocked T‐cell‐mediated antitumor activity under hypoxia in colorectal cancer

  2024cites this paper
• Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy

  2024cites this paper
• CT Image-Based Radiomic Analysis for Detecting PD-L1 Expression Status in Bladder Cancer Patients.

  2024cites this paper
• LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features

  2024cites this paper
• New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer.

  2024cites this paper
• Application Value of 18F-FDG PET/CT in Non-Small Cell Lung Cancer

  2024cites this paper
• Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis

  2023cites this paper
• Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials.

  2023cites this paper
• The Emerging Role of Raman Spectroscopy as an Omics Approach for Metabolic Profiling and Biomarker Detection toward Precision Medicine.

  2023cites this paper
• Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging

  2023cites this paper
• Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic features

  2023cites this paper
• The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis

  2023cites this paper
• A pH-responsive nanocarrier synergistically activate tumor immunotherapy by promoting pyroptosis and immune checkpoint blocking

  2023cites this paper
• TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer.

  2023cites this paper
• Programmed Cell Death 1 checkpoint inhibitors as cancer therapies

  2023cites this paper
• Characteristics and postoperative dynamic changes in circulating CD4+ helper T lymphocytes in patients with breast cancer

  2023cites this paper
• PD‐L1 expression downregulation by RNF43 in gastric carcinoma enhances antitumour activity of T cells

  2023cites this paper
• Highly Sensitive Detection of the Immune Checkpoint PD-L1-Positive Circulating Tumor Cells Based on Steric Hindrance.

  2022cites this paper
• Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?

  2022cites this paper
• Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma

  2022cites this paper
• Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor Activity

  2022cites this paper
• OncoTherad^® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer

  2022cites this paper
• Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma

  2022cites this paper
• PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

  2021cites this paper
• Kronik Lenfositik Lösemide PD-1/PD-L1 Ekspresyon Düzeyleri ve Prognostik Önemi

  2021cites this paper
• PD-L1 expression in angiomatoid fibrous histiocytoma

  2021cites this paper
• Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma

  2021cites this paper
• Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review

  2021cites this paper
• CRISPRi-mediated knock-down of PRDM1/BLIMP1 programs central memory differentiation in ex vivo-expanded human T cells

  2021cites this paper
• Клинико-прогностический анализ экспрессии PD-L1 и COX‑2

  2021cites this paper
• Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies

  2021cites this paper
• Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade

  2021cites this paper
• A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract

  2021influential citation
• The Epithelial–Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment

  2021cites this paper
• Characteristics of Lower Extremity Infection Rates Following Mohs Micrographic Surgery

  2021cites this paper
• Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non–small cell lung cancer: A systematic review and meta-analysis

  2021cites this paper
• Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project.

  2021cites this paper
• Durable complete response to immunotherapy with anti‐PD‐1 antibody nivolumab in a patient with oral squamous cell carcinoma presenting with lung metastasis: A case report

  2021cites this paper
• Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features

  2021cites this paper
• Systemic Therapy for Locally Advanced and Metastatic Non-Melanoma Skin Cancer

  2021cites this paper
• M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

  2021cites this paper
• Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

  2021cites this paper
• Cancer microenvironment and genomics: evolution in process

  2021cites this paper
• Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.

  2021cites this paper
• Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC

  2020cites this paper
• Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma

  2020cites this paper
• Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay

  2020cites this paper
• Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer

  2020cites this paper
• Systematic analysis of the transcriptome in small‐cell carcinoma of the oesophagus reveals its immune microenvironment

  2020cites this paper
• Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study

  2020cites this paper
• PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer

  2020cites this paper
• Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.

  2020cites this paper
• Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade.

  2020cites this paper
• Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo

  2020cites this paper
• Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.

  2020cites this paper
• PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature

  2020cites this paper
• Androgen receptor expression inversely correlates with immune cell infiltration in HER2-positive breast cancer

  2020cites this paper
• Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors

  2020cites this paper
• PD-L1 Immunohistochemistry Assay Comparison Studies in Non-Small Cell Lung Cancer: Characterization of the 73-10 Assay.

  2020cites this paper
• PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas.

  2020cites this paper
• Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy

  2020cites this paper
• Breast Tumor Microenvironment: Emerging target of therapeutic phytochemicals.

  2020cites this paper
• OTT_A_261068 12003..12013

  2020cites this paper
• Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy

  2020cites this paper
• Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers.

  2020cites this paper
• Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

  2020cites this paper
• Macroscopic fluorescence lifetime-based Förster resonance energy transfer imaging for quantitative ligand–receptor binding

  2020cites this paper
• Phase 2 study of pembrolizumab in patients with advanced rare cancers

  2020cites this paper
• PET imaging of immune checkpoint proteins in oncology.

  2020cites this paper
• Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T

  2020cites this paper
• The emerging development of tumor mutational burden in patients with NSCLC.

  2020cites this paper
• A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer

  2019influential citation
• Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC

  2019cites this paper
• Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer

  2019cites this paper
• Immunotherapy in extensive small cell lung cancer

  2019cites this paper
• Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer

  2019cites this paper
• Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma

  2019cites this paper
• Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients

  2019cites this paper
• Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

  2019cites this paper
• Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma

  2019cites this paper
• Emerging therapies for non-small cell lung cancer

  2019cites this paper
• Can CpG methylation serve as surrogate markers for immune infiltration in cancer?

  2019cites this paper
• Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

  2019cites this paper
• PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer

  2019cites this paper
• Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events

  2019cites this paper
• A skewed distribution and increased PD‐1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia

  2019cites this paper